These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 37385959)

  • 21. Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview.
    Davidson JA; Sloan L
    Adv Ther; 2017 Jan; 34(1):41-59. PubMed ID: 27854055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First-line treatment for type 2 diabetes: is it too early to abandon metformin?
    Zaccardi F; Khunti K; Marx N; Davies MJ
    Lancet; 2020 Nov; 396(10264):1705-1707. PubMed ID: 33248483
    [No Abstract]   [Full Text] [Related]  

  • 23. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
    Gebrie D; Getnet D; Manyazewal T
    Sci Rep; 2021 Jan; 11(1):137. PubMed ID: 33420333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.
    Ridderstråle M; Svaerd R; Zeller C; Kim G; Woerle HJ; Broedl UC;
    Cardiovasc Diabetol; 2013 Sep; 12():129. PubMed ID: 24007456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin].
    Nauck M; del Prato S; Meier JJ; Durán-García S; Rohwedder K; Elze M; Parikh SJ
    Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S6-15. PubMed ID: 23529570
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England.
    Heald AH; Fryer AA; Anderson SG; Livingston M; Lunt M; Davies M; Moreno GYC; Gadsby R; Young RJ; Stedman M
    Diabetes Obes Metab; 2018 Jul; 20(7):1659-1669. PubMed ID: 29516618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.
    Packer M
    Diabetes Obes Metab; 2018 Jun; 20(6):1361-1366. PubMed ID: 29359851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases.
    Prattichizzo F; La Sala L; Rydén L; Marx N; Ferrini M; Valensi P; Ceriello A
    Eur J Prev Cardiol; 2019 Dec; 26(2_suppl):73-80. PubMed ID: 31766918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ertugliflozin for the treatment of type 2 diabetes.
    Sharma R; Razdan K; Kuhad A; Kuhad A
    Drugs Today (Barc); 2019 Mar; 55(3):167-175. PubMed ID: 30938372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study.
    Chen TH; Li YR; Chen SW; Lin YS; Sun CC; Chen DY; Mao CT; Wu M; Chang CH; Chu PH; Wu VC
    Cardiovasc Diabetol; 2020 Nov; 19(1):189. PubMed ID: 33167990
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes.
    Nauck MA
    Drug Des Devel Ther; 2014; 8():1335-80. PubMed ID: 25246775
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Factors Associated with Initial Decrease in Body-Fat Percentage Induced by Add-on Sodium-Glucose Co-transporter 2 Inhibitors in Patient with Type 2 Diabetes Mellitus.
    Kurinami N; Sugiyama S; Nishimura H; Morita A; Yoshida A; Hieshima K; Miyamoto F; Kajiwara K; Jinnouchi K; Jinnouchi T; Jinnouchi H
    Clin Drug Investig; 2018 Jan; 38(1):19-27. PubMed ID: 29098566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meta-analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add-on to metformin in type 2 diabetes.
    Zhou Y; Geng Z; Wang X; Huang Y; Shen L; Wang Y
    Diabetes Metab Res Rev; 2020 Feb; 36(2):e3223. PubMed ID: 31642583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study.
    Pérez-Belmonte LM; Torres-Peña JD; López-Carmona MD; Ayala-Gutiérrez MM; Fuentes-Jiménez F; Jorge Huerta L; Muñoz JA; Rubio-Rivas M; Madrazo M; Garcia MG; Montes BV; Sola JF; Ena J; Ferrer RG; Pérez CM; Ripper CJ; Lecumberri JJN; Acedo IEA; Canteli SP; Cosío SF; Martínez FA; Rodríguez BC; Pérez-Martínez P; Ramos-Rincón JM; Gómez-Huelgas R;
    BMC Med; 2020 Nov; 18(1):359. PubMed ID: 33190637
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SGLT2 inhibitors in the management of type 2 diabetes.
    Monica Reddy RP; Inzucchi SE
    Endocrine; 2016 Aug; 53(2):364-72. PubMed ID: 27270407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
    Pratley RE; Eldor R; Raji A; Golm G; Huyck SB; Qiu Y; Sunga S; Johnson J; Terra SG; Mancuso JP; Engel SS; Lauring B
    Diabetes Obes Metab; 2018 May; 20(5):1111-1120. PubMed ID: 29266675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Management of hyperglycaemia with non-insulin drugs in adult patients with type 2 diabetes].
    Álvarez-Guisasola F; Orozco-Beltrán D; Cebrián-Cuenca AM; Ruiz Quintero MA; Angullo Martínez E; Ávila Lachica L; Ortega Millán C; Caride Miana E; Navarro-Pérez J; Sagredo Perez J; Barrot de la Puente J; Cos Claramunt FX
    Aten Primaria; 2019; 51(7):442-451. PubMed ID: 31320123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Possible association between diabetic ketoacidosis and use of sodium-glucose co-transporter 2 inhibitor in a 17-year-old youth with type 2 diabetes.
    Shamchuk A; Doulla M; Jetha M
    CMAJ; 2021 Sep; 193(35):E1385-E1388. PubMed ID: 34493565
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparison of exenatide and acarbose on intra-abdominal fat content in patients with obesity and type-2 diabetes: A randomized controlled trial.
    Shi L; Zhu J; Yang P; Tang X; Yu W; Pan C; Shen M; Zhu D; Cheng J; Ye X
    Obes Res Clin Pract; 2017; 11(5):607-615. PubMed ID: 28161303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A registry-based randomised trial comparing an SGLT2 inhibitor and metformin as standard treatment of early stage type 2 diabetes (SMARTEST): Rationale, design and protocol.
    Sundström J; Kristófi R; Östlund O; Bennet L; Eliasson B; Jansson S; Leksell J; Almby K; Lundqvist M; Eriksson JW;
    J Diabetes Complications; 2021 Oct; 35(10):107996. PubMed ID: 34389234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.